Arkolith/Insider Trading/KNSA/Form 4

Patel Sanj K

CHAIRMAN & CEO, DirectorKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Oct 22, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10.0M
Net Open-Market Flow
-$10.0M
Transactions
10
7 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 22, 2025Sell(S)97K$38.83$3.8M112K
Oct 22, 2025Option exercise(M)97K$3.80$370K209K
Oct 21, 2025Sell(S)39K$38.77$1.5M112K
Oct 21, 2025Option exercise(M)39K$3.80$149K151K
Oct 20, 2025Option exercise(M)121K$3.80$461K233K
Oct 20, 2025Sell(S)99K$38.81$3.8M134K
Oct 20, 2025Sell(S)22K$39.32$877K112K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 22, 2025Option exercise(M)97K—$00
Oct 21, 2025Option exercise(M)39K—$097K
Oct 20, 2025Option exercise(M)121K—$0137K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001532218-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML